Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Age-related tumor growth in mice is related to integrin α 4 in CD8+ T cells
Juhyun Oh, Angela Magnuson, Christophe Benoist, Mikael J. Pittet, Ralph Weissleder
Juhyun Oh, Angela Magnuson, Christophe Benoist, Mikael J. Pittet, Ralph Weissleder
View: Text | PDF
Research Article Aging Immunology

Age-related tumor growth in mice is related to integrin α 4 in CD8+ T cells

  • Text
  • PDF
Abstract

Cancer incidence increases with age, but paradoxically, cancers have been found to grow more quickly in young mice compared with aged ones. The cause of differential tumor growth has been debated and, over time, attributed to faster tumor cell proliferation, decreased tumor cell apoptosis, and/or increased angiogenesis in young animals. Despite major advances in our understanding of tumor immunity over the past 2 decades, little attention has been paid to comparing immune cell populations in young and aged mice. Using mouse colon adenocarcinoma model MC38 implanted in young and mature mice, we show that age substantially influences the number of tumor-infiltrating cytotoxic CD8+ T cells, which control cancer progression. The different tumor growth pace in young and mature mice was abrogated in RAG1null mice, which lack mature T and B lymphocytes, and upon selective depletion of endogenous CD8+ cells. Transcriptome analysis further indicated that young mice have decreased levels of the Itga4 gene (CD49d, VLA-4) in tumor-infiltrating lymphocytes when compared with mature mice. Hypothesizing that VLA-4 can have a tumor-protective effect, we depleted the protein, which resulted in accelerated tumor growth in mature mice. These observations may explain the paradoxical growth rates observed in murine cancers, point to the central role of VLA-4 in controlling tumor growth, and open new venues to therapeutic manipulation.

Authors

Juhyun Oh, Angela Magnuson, Christophe Benoist, Mikael J. Pittet, Ralph Weissleder

×

Figure 2

Increased CD8+ T cell infiltration controls MC38 tumor growth in mature mice.

Options: View larger image (or click on image) Download as PowerPoint
Increased CD8+ T cell infiltration controls MC38 tumor growth in mature ...
Numbers of tumor-infiltrating cells per mm3 of tumor tissue counted at days 7, 14, and 21 of tumor growth show changes in immune infiltration over time. (A) CD8+ T cell (CD45+TCRβ+CD8+; day7: young n = 7 (red circle), mature n = 11 (blue square); day 14: n = 18 per group; day 21: young n = 17, mature n = 14). (B) CD4+ T cell (CD45+TCRβ+CD4+; day7: young n = 7, mature n = 11; day 14: n = 18 per group; day 21: young n = 17, mature n = 14). (C) Treg (CD45+TCRβ+CD4+CD25+FoxP3+; day7: n = 6 per group; day 14: n = 5 per group; day 21: young n = 9, mature n = 5). (D) Tumor-associated macrophage (CD45+CD11b+F4/80+MHCII+; day7: n = 10 per group; day 14: n = 16 per group; day 21: young n = 13, mature n = 10). (E) DC (CD45+CD11c+MHCIIhi; day7: n = 9 per group; day 14: n = 11 per group; day 21: young n = 13, mature n = 9). (F) Tumors of similar sizes (40–50 mm3) from young and mature mice (at different time points of tumor growth) were compared for T cell counts per unit volume of tumor tissues. (G) MC38 tumor growth in young mice treated with anti-CD8 antibody (green circle) or IgG isotype control antibody (red circle; n = 9 per group). (H) MC38 tumor growth in aged mice treated with anti-CD8 antibody (green square) or IgG isotype control (blue square; n = 6 per group). (I) Superimposed MC38 tumor growth curves of young and mature mice with CD8 depletion shows that CD8 depletion eliminates age-dependent differences in tumor growth rate. Dotted line shows the exponential model fit to the tumor size data points of young C57BL/6 mice from Figure 1A. All data are plotted as means ± SEM. For statistical test, t test (2-tailed) was used with correction for multiple comparisons by Holm-Sidak method (*P < 0.05, **P < 0.005, ***P < 0.0005).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts